Transformative Fingertip Blood Collection Device Produces Lab-Quality Test Results
|
By LabMedica International staff writers Posted on 08 Dec 2023 |

The traditional process of "blood work" for patients typically involves a visit to a laboratory service center where a professional, such as a nurse or phlebotomist, draws blood from the patient's vein. Now, a new blood collection device is set to revolutionize this standard procedure by allowing blood testing in more accessible and convenient locations, offering advantages for patients, healthcare providers, and collection sites.
Becton, Dickinson and Company’s (BD, Franklin Lakes, NJ, USA) BD MiniDraw Capillary Blood Collection System is an innovative device that collects blood samples through a fingerstick, yielding laboratory-quality results for several common blood tests. Unlike the conventional venous blood draw, this system is less invasive, utilizing capillary blood from the patient's finger, which can be done by a trained healthcare worker without the need for a vein puncture by a phlebotomist. The device’s design enables the acquisition of lab-quality results from a smaller blood volume than what is typically required for venous collections. Moreover, it offers more convenience to patients by allowing blood collection at new venues, such as retail pharmacies, potentially enhancing the overall patient experience and revolutionizing diagnostic testing.
The use of the BD MiniDraw Collection System benefits patients by enabling them to have blood drawn in familiar places they frequently visit, like retail pharmacies or grocery stores. These locations often have extended operating hours and may be more conveniently located near their homes or workplaces. For these alternative collection sites, such as retail settings, the system not only complements existing health and wellness programs, like vaccine administration but also has the potential to increase foot traffic. Healthcare providers can benefit too, as capillary blood collection could be offered right in a physician's office without needing specialized phlebotomy staff. This ease and reduced invasiveness of the process might lead to improved patient compliance with blood testing, which is crucial for regular health assessments and could aid in the early detection and better management of chronic diseases.
BD has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the BD MiniDraw Collection System. This clearance covers low-volume blood collection for various tests, including lipid panels, select chemistry tests, and hemoglobin and hematocrit (H&H) testing, which are some of the most frequently requested laboratory tests. They are essential for diagnosing and monitoring various chronic conditions, from hypertension to high cholesterol. Looking ahead, BD aims to broaden the range of blood tests facilitated by the BD MiniDraw Collection System.
"Because the BD MiniDraw Collection System enables blood collection at non-traditional sites that may be more convenient—like your local pharmacy rather than a standalone lab—we can expand health equity and access, and make it easier for patients to get the blood tests they need both for preventative care and the management of chronic conditions," said Dave Hickey, executive vice president and president of Life Sciences for BD. "This innovation is our strategy and pipeline coming to life, and proof of our commitment to enabling diagnostics and care in alternate settings."
Related Links:
BD
Latest Pathology News
- Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
- AI Links Organ-Specific Aging Patterns in Histology to Blood-Based Signals
- 30-Minute 3D Histology Tool Supports Intraoperative Glioma Margin Assessment
- AI Uses H&E Slides to Predict Key Biomarkers Across 32 Cancers
- AI Tool Identifies Slide Artifacts to Speed Digital Pathology Diagnosis
- FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis
- AI Pathology Tool Predicts Relapse Risk in Stage II Colorectal Cancer
- AI Pathology Tool Stratifies Rectal Cancer to Guide Chemoradiotherapy
- PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
- AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
- AI Bone Marrow Mapping Provides New Tool to Track Blood Cancer Severity
- Digital Pathology Tool Predicts Breast Cancer Outcomes and Therapy Response
- AI Tissue Imaging Helps Guide Targeted Therapy for Lung Cancer
- Imaging Platform Maps Lipid Accumulations in Fabry Heart Tissue
- Tissue-Based Gene Signature Signals Colorectal Cancer Recurrence Risk
- FDA-Approved Companion Diagnostic Detects PTEN Loss in Prostate Cancer
Channels
Clinical Chemistry
view channel
Longitudinal Heart Stress Assessment Improves Prediction of Cardiovascular Outcomes
Accurately predicting cardiovascular disease (CVD) risk in older adults is challenging when assessments rely on single, point-in-time biomarker measurements. Dynamic indicators that reflect evolving cardiac... Read more
Blood Test Measuring Tumor Proliferation May Guide Treatment Sequencing in Metastatic Melanoma
Metastatic melanoma remains difficult to manage because outcomes vary widely and early prognostic markers are limited. About half of patients carry a BRAF gene mutation, giving clinicians several first-line... Read moreMolecular Diagnostics
view channel
Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Timely cervical cancer screening prevents progression from persistent high‑risk human papillomavirus (HPV) infection, yet many adults marginalized from care do not complete routine exams.... Read more
Comprehensive Genomic Testing Expands Treatment Options for Advanced Cancers
Selecting effective therapies for advanced cancers remains difficult because standard tumor testing often targets only a limited set of genes. As options dwindle, many patients face decisions without strong... Read more
Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer
Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Machine Learning Approach Expands Epigenetic Testing for Prenatal Genetic Disorders
Prenatal genetic testing is increasingly used to identify potential neurodevelopmental conditions, but results often include variants of uncertain significance that clinicians cannot confidently classify.... Read moreHematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read moreImmunology
view channel
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Immune Cell Blood Test May Predict Melanoma Immunotherapy Response
Melanoma remains one of the deadliest skin cancers, although outcomes improve markedly when the disease is detected early. Immunotherapy has extended survival for many patients with advanced melanoma,... Read moreMicrobiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read moreTechnology
view channel
Interoperable Data Platform Standardizes Multi-Cancer Blood Test Results
Proteotype Diagnostics has introduced Alchemi, a proprietary data and clinical workflow platform being developed for Enlighten, the company’s investigational blood-based multi-cancer test.... Read more
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
CellCarta, a global CRO laboratory serving the biopharmaceutical industry, has announced a strategic collaboration with Tempus AI to broaden access to companion diagnostics (CDx) in oncology.... Read more







